Category: parkinson’s

Colorado: Health Officials Recommend $7.5 Million In Grant Funding For Clinical Cannabis Trials

State Public Health Department officials have recommended over $7 million dollars in grant funding to pay for a series of state-sponsored clinical trials to assess the safety and efficacy of cannabis and cannabinoids. The proposed studies include a pair of clinical trials to evaluate the use of cannabidiol (CBD), a nonpsychotropic plant cannabinoid, for patients with pediatric epilepsy. Two additional trials will assess the use of cannabis for patients suffering from post-traumatic stress. Other studies will assess the efficacy of either cannabis or CBD in the treatment of Parkinson’s disease, brain tumors, ulcerative colitis, and pain management.

Study: CBD Administration Associated With Improved Quality Of Life In Patients With Parkinson’s Disease

The administration of cannabidiol (CBD), a nonpsychotropic cannabinoid, is associated with improved quality of life in patients with Parkinson’s disease, according clinical trial data published online ahead of print in the Journal of Psychopharmacology. Authors reported that the administration of 300 mg doses of CBD per day was associated with “significantly different mean total scores” in subjects’ well-being and quality of life compared to placebo.

Study: Inhaled Cannabis Mitigates Parkinson’s Disease Symptoms

Inhaling whole-plant cannabis provides symptomatic relief in patients with Parkinson’s disease (PD), according to observational trial data published in the March/April edition of the journal Clinical Neuropharmacology. Researchers reported that inhaled cannabis was associated with “significant improvement after treatment in tremor, rigidity, and bradykinsea (slowness of movement). There was also significant improvement of sleep and pain scores. No significant adverse effects of the drug were observed.”

Maine: Medical Marijuana Program Expanded To Include Patients With PTSD, Other Debilitating Disorders

Patients diagnosed with post-traumatic stress, Crohn’s disease, and other debilitating disorders will now be eligible for cannabis therapy, under legislation approved yesterday absent the Governor’s signature. The new law expands the list of qualifying conditions for which a Maine physician may legally recommend cannabis to include “post-traumatic stress disorder,” “inflammatory bowel disease” (such as Crohn’s and/or ulcerative colitis), and “dyskinetic and spastic movement disorders and other diseases causing severe and persistent muscle spasms” (such as Parkinson’s disease and/or Huntington’s disease).